Recent Biopharma Funding Activity
20 public and private funding events 👇
– Private Funding –
Clasp Therapeutics
🏦 Launched w/ $150M Series A financing from several investors to develop their T-cell engagers (TCE) pipeline.
Clasp Therapeutics
🏦 Launched w/ $150M Series A financing from several investors to develop their T-cell engagers (TCE) pipeline.
Capstan Therapeutics
🏦 Closed $175M Series B financing led by RA Capital Management to support the advancement of CPTX2309, their in vivo CAR-T product candidate.
🏦 Closed $175M Series B financing led by RA Capital Management to support the advancement of CPTX2309, their in vivo CAR-T product candidate.
Engrail Therapeutics
🏦 Closed $157M Series B financing round to advance the development of their therapies.
🏦 Closed $157M Series B financing round to advance the development of their therapies.
Pandorum
🏦 Secured $11M pre-series B financing to advance regenerative therapy for corneal blindness.
🏦 Secured $11M pre-series B financing to advance regenerative therapy for corneal blindness.
Nouscom
🏦 Raised $82M (€75.8M) Series C financing led by Angelini Ventures to continue advancing their current pipeline.
🏦 Raised $82M (€75.8M) Series C financing led by Angelini Ventures to continue advancing their current pipeline.
Portal Biotechnologies
🏦 Raised $5M pre-seed round led by Pear VC to continue the development and commercialization of their cell engineering platform.
🏦 Raised $5M pre-seed round led by Pear VC to continue the development and commercialization of their cell engineering platform.
MITRO Biotech
🏦 Raised $55M (¥400M) for innovative drug development.
🏦 Raised $55M (¥400M) for innovative drug development.
SENISCA
🏦 Secured additional $3.7M funding from multiple investors to advance their senotherapeutic programs.
🏦 Secured additional $3.7M funding from multiple investors to advance their senotherapeutic programs.
Oncostellae
🏦 Secured $540K (€500K) funding from CDTI Innovation and Bio & Tech Smart Capital to continue the development of OST-499, OST-664, and OST-122.
🏦 Secured $540K (€500K) funding from CDTI Innovation and Bio & Tech Smart Capital to continue the development of OST-499, OST-664, and OST-122.
– Debt Financing –
bluebird bio
🏦 Secured $175M through debt financing with Hercules Capital to execute commercial launches of LYFGENIA, ZYNTEGLO, and SKYSONA.
bluebird bio
🏦 Secured $175M through debt financing with Hercules Capital to execute commercial launches of LYFGENIA, ZYNTEGLO, and SKYSONA.
– Grant Funding –
SolasCure
🏦 Awarded ~$500K (£405K) biomedical catalyst grant from Innovate UK to advance Aurase wound gel development.
SolasCure
🏦 Awarded ~$500K (£405K) biomedical catalyst grant from Innovate UK to advance Aurase wound gel development.
– Public/Equity Financing –
Madrigal Pharmaceuticals
🏦 $600M public offering announced to fund the launch of Rezdiffra™ (resmetirom) in the U.S. and general corporate purposes.
Madrigal Pharmaceuticals
🏦 $600M public offering announced to fund the launch of Rezdiffra™ (resmetirom) in the U.S. and general corporate purposes.
Mirador Therapeutics
🏦 Raised $400M in funds through financing led by ARCH Venture Partners and other investors.
🏦 Raised $400M in funds through financing led by ARCH Venture Partners and other investors.
Spyre Therapeutics
🏦 $180M PIPE financing.
🏦 $180M PIPE financing.
Outlook Therapeutics
🏦 Closed $159M private placement led by Great Point Partners, LLC. to fund their ONS-5010 program.
🏦 Closed $159M private placement led by Great Point Partners, LLC. to fund their ONS-5010 program.
Geron Corporation
🏦 $150M public offering to fund potential commercialization of Imetelstat in the US and EU and general corporate purposes.
🏦 $150M public offering to fund potential commercialization of Imetelstat in the US and EU and general corporate purposes.
Fate Therapeutics
🏦 $100M offering and concurrent private placement to fund clinical and non-clinical studies.
🏦 $100M offering and concurrent private placement to fund clinical and non-clinical studies.
Enliven Therapeutics
🏦 $90M private placement financing to fund its current drug pipeline.
🏦 $90M private placement financing to fund its current drug pipeline.
Sangamo Therapeutics
🏦 $24M registered direct offering announced to fund its neuro-focused genomic medicines pipeline, novel AAV capsid delivery technology, and other general corporate purposes.
🏦 $24M registered direct offering announced to fund its neuro-focused genomic medicines pipeline, novel AAV capsid delivery technology, and other general corporate purposes.
Sellas Life Sciences
🏦 Closed $20M direct offering and private placement.
🏦 Closed $20M direct offering and private placement.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
